Dividend29 May 2026, 09:31 pm
Glenmark Pharma Recommends ₹2.5 Dividend for FY26
AI Summary
Glenmark Pharmaceuticals Ltd's Board of Directors, in its meeting on May 29, 2026, recommended a dividend of ₹2.5 per share (face value of Re. 1 each) on the equity shares for the financial year 2025-26, subject to shareholder approval. The board also approved the audited financial results for the quarter and year ended March 31, 2026. The company's standalone revenue from operations for FY26 was ₹84,400.99 million, with a net loss after tax of ₹2,007.99 million.
Key Highlights
- Glenmark Pharma recommends a dividend of ₹2.5 per share for FY26.
- Board approved audited financial results for Q4 and FY26 on May 29, 2026.
- Standalone revenue from operations for FY26 stood at ₹84,400.99 million.
- The company reported a standalone net loss after tax of ₹2,007.99 million for FY26.
- Meeting commenced at 04:30 p.m. and concluded at 07:26 p.m.
Price Impact
More from GLENMARK